Leukocyte immunoglobulin-like receptor subfamily B member 1

<p>This section provides any useful information about the protein, mostly biological knowledge.<p><a href='/help/function_section' target='_top'>More...</a></p>Functionⁱ

<p>The <a href="http://www.geneontology.org/">Gene Ontology (GO)</a> project provides a set of hierarchical controlled vocabulary split into 3 categories:<p><a href='/help/gene_ontology' target='_top'>More...</a></p>GO - Molecular functionⁱ

• HLA-A specific inhibitory MHC class I receptor activity Source: UniProtKB <p>Inferred from Direct Assay</p> <p>Used to indicate a direct assay for the function, process or component indicated by the GO term.</p> <p>More information in the <a href="http://geneontology.org/page/guide-go-evidence-codes#ida">GO evidence code guide</a></p> Inferred from direct assayⁱ
  • "HLA class I molecules regulate IFN-gamma production induced in NK cells by target cells, viral products, or immature dendritic cells through the inhibitory receptor ILT2/CD85j."
    Morel E., Bellon T.
    J. Immunol. 181:2368-2381(2008) [PubMed] [Europe PMC] [Abstract]
• HLA-B specific inhibitory MHC class I receptor activity Source: UniProtKBInferred from direct assayⁱ
  • Ref.11

    "Mutational analysis of immunoreceptor tyrosine-based inhibition motifs of the Ig-like transcript 2 (CD85j) leukocyte receptor."
    Bellon T., Kitzig F., Sayos J., Lopez-Botet M.
    J. Immunol. 168:3351-3359(2002) [PubMed] [Europe PMC] [Abstract]

    Cited for: PHOSPHORYLATION AT TYR-533; TYR-614 AND TYR-644, MUTAGENESIS OF TYR-533; TYR-562; TYR-614 AND TYR-644, INTERACTION WITH FCER1A, FUNCTION.
• MHC class Ib protein binding Source: UniProtKBInferred from direct assayⁱ
  • "Functional characterization of HLA-F and binding of HLA-F tetramers to ILT2 and ILT4 receptors."
    Lepin E.J., Bastin J.M., Allan D.S., Roncador G., Braud V.M., Mason D.Y., van der Merwe P.A., McMichael A.J., Bell J.I., Powis S.H., O'Callaghan C.A.
    Eur. J. Immunol. 30:3552-3561(2000) [PubMed] [Europe PMC] [Abstract]
• MHC class Ib protein complex binding Source: UniProtKBInferred from direct assayⁱ
  • "Structural basis for recognition of the nonclassical MHC molecule HLA-G by the leukocyte Ig-like receptor B2 (LILRB2/LIR2/ILT4/CD85d)."
    Shiroishi M., Kuroki K., Rasubala L., Tsumoto K., Kumagai I., Kurimoto E., Kato K., Kohda D., Maenaka K.
    Proc. Natl. Acad. Sci. U.S.A. 103:16412-16417(2006) [PubMed] [Europe PMC] [Abstract]
  • Ref.17

    "Human Leukocyte Antigen F Presents Peptides and Regulates Immunity through Interactions with NK Cell Receptors."
    Dulberger C.L., McMurtrey C.P., Holzemer A., Neu K.E., Liu V., Steinbach A.M., Garcia-Beltran W.F., Sulak M., Jabri B., Lynch V.J., Altfeld M., Hildebrand W.H., Adams E.J.
    Immunity 46:1018-1029(2017) [PubMed] [Europe PMC] [Abstract]

    Cited for: FUNCTION, SUBUNIT, INTERACTION WITH HLA-F.
• MHC class Ib receptor activity Source: UniProtKBInferred from direct assayⁱ
  • Ref.15

    "Binding of HLA-G to ITIM-bearing Ig-like transcript 2 receptor suppresses B cell responses."
    Naji A., Menier C., Morandi F., Agaugue S., Maki G., Ferretti E., Bruel S., Pistoia V., Carosella E.D., Rouas-Freiss N.
    J. Immunol. 192:1536-1546(2014) [PubMed] [Europe PMC] [Abstract]

    Cited for: FUNCTION, TISSUE SPECIFICITY, SUBCELLULAR LOCATION.
• MHC class I protein binding Source: UniProtKBInferred from direct assayⁱ
  • "The inhibitory receptor LILRB1 modulates the differentiation and regulatory potential of human dendritic cells."
    Young N.T., Waller E.C., Patel R., Roghanian A., Austyn J.M., Trowsdale J.
    Blood 111:3090-3096(2008) [PubMed] [Europe PMC] [Abstract]
  • "Inhibitory immunoglobulin-like receptors LILRB and PIR-B negatively regulate osteoclast development."
    Mori Y., Tsuji S., Inui M., Sakamoto Y., Endo S., Ito Y., Fujimura S., Koga T., Nakamura A., Takayanagi H., Itoi E., Takai T.
    J. Immunol. 181:4742-4751(2008) [PubMed] [Europe PMC] [Abstract]
  • "High affinity soluble ILT2 receptor: a potent inhibitor of CD8(+) T cell activation."
    Moysey R.K., Li Y., Paston S.J., Baston E.E., Sami M.S., Cameron B.J., Gavarret J., Todorov P., Vuidepot A., Dunn S.M., Pumphrey N.J., Adams K.J., Yuan F., Dennis R.E., Sutton D.H., Johnson A.D., Brewer J.E., Ashfield R., Lissin N.M., Jakobsen B.K.
    Protein Cell 1:1118-1127(2010) [PubMed] [Europe PMC] [Abstract]
  • Ref.9

    "The MHC class I binding proteins LIR-1 and LIR-2 inhibit Fc receptor-mediated signaling in monocytes."
    Fanger N.A., Cosman D., Peterson L., Braddy S.C., Maliszewski C.R., Borges L.
    Eur. J. Immunol. 28:3423-3434(1998) [PubMed] [Europe PMC] [Abstract]

    Cited for: INTERACTION WITH PTPN6 AND FCGR1A, PHOSPHORYLATION, TISSUE SPECIFICITY, FUNCTION.
• MHC class I receptor activity Source: UniProtKBInferred from direct assayⁱ
  • "Structural elements underlying the high binding affinity of human cytomegalovirus UL18 to leukocyte immunoglobulin-like receptor-1."
    Wagner C.S., Rolle A., Cosman D., Ljunggren H.G., Berndt K.D., Achour A.
    J. Mol. Biol. 373:695-705(2007) [PubMed] [Europe PMC] [Abstract]
  • "The inhibitory receptor LILRB1 modulates the differentiation and regulatory potential of human dendritic cells."
    Young N.T., Waller E.C., Patel R., Roghanian A., Austyn J.M., Trowsdale J.
    Blood 111:3090-3096(2008) [PubMed] [Europe PMC] [Abstract]
  • "The CD85j+ NK cell subset potently controls HIV-1 replication in autologous dendritic cells."
    Scott-Algara D., Arnold V., Didier C., Kattan T., Pirozzi G., Barre-Sinoussi F., Pancino G.
    PLoS ONE 3:e1975-e1975(2008) [PubMed] [Europe PMC] [Abstract]
  • "Inhibitory immunoglobulin-like receptors LILRB and PIR-B negatively regulate osteoclast development."
    Mori Y., Tsuji S., Inui M., Sakamoto Y., Endo S., Ito Y., Fujimura S., Koga T., Nakamura A., Takayanagi H., Itoi E., Takai T.
    J. Immunol. 181:4742-4751(2008) [PubMed] [Europe PMC] [Abstract]
  • "High affinity soluble ILT2 receptor: a potent inhibitor of CD8(+) T cell activation."
    Moysey R.K., Li Y., Paston S.J., Baston E.E., Sami M.S., Cameron B.J., Gavarret J., Todorov P., Vuidepot A., Dunn S.M., Pumphrey N.J., Adams K.J., Yuan F., Dennis R.E., Sutton D.H., Johnson A.D., Brewer J.E., Ashfield R., Lissin N.M., Jakobsen B.K.
    Protein Cell 1:1118-1127(2010) [PubMed] [Europe PMC] [Abstract]
  • "Up-regulation of cytolytic functions of human Vdelta2-gamma T lymphocytes through engagement of ILT2 expressed by tumor target cells."
    Harly C., Peyrat M.A., Netzer S., Dechanet-Merville J., Bonneville M., Scotet E.
    Blood 117:2864-2873(2011) [PubMed] [Europe PMC] [Abstract]
  • Ref.2

    "A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules."
    Cosman D., Fanger N., Borges L., Kubin M., Chin W., Peterson L., Hsu M.-L.
    Immunity 7:273-282(1997) [PubMed] [Europe PMC] [Abstract]

    Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 3), VARIANTS PRO-68; THR-142; ILE-155 AND LYS-625, INTERACTION WITH H301 AND PTPN6, PHOSPHORYLATION, TISSUE SPECIFICITY, FUNCTION.
  • Ref.9

    "The MHC class I binding proteins LIR-1 and LIR-2 inhibit Fc receptor-mediated signaling in monocytes."
    Fanger N.A., Cosman D., Peterson L., Braddy S.C., Maliszewski C.R., Borges L.
    Eur. J. Immunol. 28:3423-3434(1998) [PubMed] [Europe PMC] [Abstract]

    Cited for: INTERACTION WITH PTPN6 AND FCGR1A, PHOSPHORYLATION, TISSUE SPECIFICITY, FUNCTION.
• protein homodimerization activity Source: UniProtKB <p>Inferred from Physical Interaction</p> <p>Covers physical interactions between the gene product of interest and another molecule (or ion, or complex).</p> <p>More information in the <a href="http://geneontology.org/page/guide-go-evidence-codes#ipi">GO evidence code guide</a></p> Inferred from physical interactionⁱ
  • "High affinity soluble ILT2 receptor: a potent inhibitor of CD8(+) T cell activation."
    Moysey R.K., Li Y., Paston S.J., Baston E.E., Sami M.S., Cameron B.J., Gavarret J., Todorov P., Vuidepot A., Dunn S.M., Pumphrey N.J., Adams K.J., Yuan F., Dennis R.E., Sutton D.H., Johnson A.D., Brewer J.E., Ashfield R., Lissin N.M., Jakobsen B.K.
    Protein Cell 1:1118-1127(2010) [PubMed] [Europe PMC] [Abstract]
• protein phosphatase 1 binding Source: UniProtKBInferred from physical interactionⁱ
  • Ref.11

    "Mutational analysis of immunoreceptor tyrosine-based inhibition motifs of the Ig-like transcript 2 (CD85j) leukocyte receptor."
    Bellon T., Kitzig F., Sayos J., Lopez-Botet M.
    J. Immunol. 168:3351-3359(2002) [PubMed] [Europe PMC] [Abstract]

    Cited for: PHOSPHORYLATION AT TYR-533; TYR-614 AND TYR-644, MUTAGENESIS OF TYR-533; TYR-562; TYR-614 AND TYR-644, INTERACTION WITH FCER1A, FUNCTION.
  • "Inhibitory immunoglobulin-like receptors LILRB and PIR-B negatively regulate osteoclast development."
    Mori Y., Tsuji S., Inui M., Sakamoto Y., Endo S., Ito Y., Fujimura S., Koga T., Nakamura A., Takayanagi H., Itoi E., Takai T.
    J. Immunol. 181:4742-4751(2008) [PubMed] [Europe PMC] [Abstract]
  • Ref.2

    "A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules."
    Cosman D., Fanger N., Borges L., Kubin M., Chin W., Peterson L., Hsu M.-L.
    Immunity 7:273-282(1997) [PubMed] [Europe PMC] [Abstract]

    Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 3), VARIANTS PRO-68; THR-142; ILE-155 AND LYS-625, INTERACTION WITH H301 AND PTPN6, PHOSPHORYLATION, TISSUE SPECIFICITY, FUNCTION.
  • Ref.9

    "The MHC class I binding proteins LIR-1 and LIR-2 inhibit Fc receptor-mediated signaling in monocytes."
    Fanger N.A., Cosman D., Peterson L., Braddy S.C., Maliszewski C.R., Borges L.
    Eur. J. Immunol. 28:3423-3434(1998) [PubMed] [Europe PMC] [Abstract]

    Cited for: INTERACTION WITH PTPN6 AND FCGR1A, PHOSPHORYLATION, TISSUE SPECIFICITY, FUNCTION.
• SH2 domain binding Source: UniProtKBInferred from direct assayⁱ
  • Ref.11

    "Mutational analysis of immunoreceptor tyrosine-based inhibition motifs of the Ig-like transcript 2 (CD85j) leukocyte receptor."
    Bellon T., Kitzig F., Sayos J., Lopez-Botet M.
    J. Immunol. 168:3351-3359(2002) [PubMed] [Europe PMC] [Abstract]

    Cited for: PHOSPHORYLATION AT TYR-533; TYR-614 AND TYR-644, MUTAGENESIS OF TYR-533; TYR-562; TYR-614 AND TYR-644, INTERACTION WITH FCER1A, FUNCTION.

GO - Biological processⁱ

• adaptive immune response Source: UniProtKB-KW
• cellular response to lipopolysaccharide Source: UniProtKB <p>Inferred from Expression Pattern</p> <p>Covers cases where the annotation is inferred from the timing or location of expression of a gene.</p> <p>More information in the <a href="http://geneontology.org/page/guide-go-evidence-codes#iep">GO evidence code guide</a></p> Inferred from expression patternⁱ
  • "The inhibitory receptor LILRB1 modulates the differentiation and regulatory potential of human dendritic cells."
    Young N.T., Waller E.C., Patel R., Roghanian A., Austyn J.M., Trowsdale J.
    Blood 111:3090-3096(2008) [PubMed] [Europe PMC] [Abstract]
• defense response to virus Source: UniProtKBInferred from direct assayⁱ
  • "Coordinated expression of Ig-like inhibitory MHC class I receptors and acquisition of cytotoxic function in human CD8+ T cells."
    Anfossi N., Doisne J.M., Peyrat M.A., Ugolini S., Bonnaud O., Bossy D., Pitard V., Merville P., Moreau J.F., Delfraissy J.F., Dechanet-Merville J., Bonneville M., Venet A., Vivier E.
    J. Immunol. 173:7223-7229(2004) [PubMed] [Europe PMC] [Abstract]
• dendritic cell differentiation Source: UniProtKBInferred from expression patternⁱ
  • "The inhibitory receptor LILRB1 modulates the differentiation and regulatory potential of human dendritic cells."
    Young N.T., Waller E.C., Patel R., Roghanian A., Austyn J.M., Trowsdale J.
    Blood 111:3090-3096(2008) [PubMed] [Europe PMC] [Abstract]
• Fc receptor mediated inhibitory signaling pathway Source: UniProtKBInferred from direct assayⁱ
  • Ref.9

    "The MHC class I binding proteins LIR-1 and LIR-2 inhibit Fc receptor-mediated signaling in monocytes."
    Fanger N.A., Cosman D., Peterson L., Braddy S.C., Maliszewski C.R., Borges L.
    Eur. J. Immunol. 28:3423-3434(1998) [PubMed] [Europe PMC] [Abstract]

    Cited for: INTERACTION WITH PTPN6 AND FCGR1A, PHOSPHORYLATION, TISSUE SPECIFICITY, FUNCTION.
• immune response-inhibiting cell surface receptor signaling pathway Source: BHF-UCL <p>Non-traceable Author Statement</p> <p>Used for statements in the abstract, introduction or discussion of a paper that cannot be traced back to another publication.</p> <p>More information in the <a href="http://geneontology.org/page/guide-go-evidence-codes#nas">GO evidence code guide</a></p> Non-traceable author statementⁱ
  • "Modulation of dendritic cell differentiation by HLA-G and ILT4 requires the IL-6--STAT3 signaling pathway."
    Liang S., Ristich V., Arase H., Dausset J., Carosella E.D., Horuzsko A.
    Proc. Natl. Acad. Sci. U.S.A. 105:8357-8362(2008) [PubMed] [Europe PMC] [Abstract]
• interferon-gamma production Source: UniProtKBInferred from direct assayⁱ
  • Ref.11

    "Mutational analysis of immunoreceptor tyrosine-based inhibition motifs of the Ig-like transcript 2 (CD85j) leukocyte receptor."
    Bellon T., Kitzig F., Sayos J., Lopez-Botet M.
    J. Immunol. 168:3351-3359(2002) [PubMed] [Europe PMC] [Abstract]

    Cited for: PHOSPHORYLATION AT TYR-533; TYR-614 AND TYR-644, MUTAGENESIS OF TYR-533; TYR-562; TYR-614 AND TYR-644, INTERACTION WITH FCER1A, FUNCTION.
• interferon-gamma secretion Source: UniProtKBInferred from direct assayⁱ
  • "Coordinated expression of Ig-like inhibitory MHC class I receptors and acquisition of cytotoxic function in human CD8+ T cells."
    Anfossi N., Doisne J.M., Peyrat M.A., Ugolini S., Bonnaud O., Bossy D., Pitard V., Merville P., Moreau J.F., Delfraissy J.F., Dechanet-Merville J., Bonneville M., Venet A., Vivier E.
    J. Immunol. 173:7223-7229(2004) [PubMed] [Europe PMC] [Abstract]
• negative regulation of alpha-beta T cell activation Source: UniProtKBInferred from direct assayⁱ
  • "High affinity soluble ILT2 receptor: a potent inhibitor of CD8(+) T cell activation."
    Moysey R.K., Li Y., Paston S.J., Baston E.E., Sami M.S., Cameron B.J., Gavarret J., Todorov P., Vuidepot A., Dunn S.M., Pumphrey N.J., Adams K.J., Yuan F., Dennis R.E., Sutton D.H., Johnson A.D., Brewer J.E., Ashfield R., Lissin N.M., Jakobsen B.K.
    Protein Cell 1:1118-1127(2010) [PubMed] [Europe PMC] [Abstract]
• negative regulation of calcium ion transport Source: UniProtKBInferred from direct assayⁱ
  • Ref.9

    "The MHC class I binding proteins LIR-1 and LIR-2 inhibit Fc receptor-mediated signaling in monocytes."
    Fanger N.A., Cosman D., Peterson L., Braddy S.C., Maliszewski C.R., Borges L.
    Eur. J. Immunol. 28:3423-3434(1998) [PubMed] [Europe PMC] [Abstract]

    Cited for: INTERACTION WITH PTPN6 AND FCGR1A, PHOSPHORYLATION, TISSUE SPECIFICITY, FUNCTION.
• negative regulation of CD8-positive, alpha-beta T cell activation Source: UniProtKBInferred from direct assayⁱ
  • "High affinity soluble ILT2 receptor: a potent inhibitor of CD8(+) T cell activation."
    Moysey R.K., Li Y., Paston S.J., Baston E.E., Sami M.S., Cameron B.J., Gavarret J., Todorov P., Vuidepot A., Dunn S.M., Pumphrey N.J., Adams K.J., Yuan F., Dennis R.E., Sutton D.H., Johnson A.D., Brewer J.E., Ashfield R., Lissin N.M., Jakobsen B.K.
    Protein Cell 1:1118-1127(2010) [PubMed] [Europe PMC] [Abstract]
• negative regulation of cell cycle Source: UniProtKBInferred from direct assayⁱ
  • "Analysis of expression and function of the inhibitory receptor ILT2 in lymphocytes from patients with autoimmune thyroid disease."
    Doniz-Padilla L., Paniagua A.E., Sandoval-Correa P., Monsivais-Urenda A., Leskela S., Marazuela M., Gonzalez-Amaro R.
    Eur. J. Endocrinol. 165:129-136(2011) [PubMed] [Europe PMC] [Abstract]
• negative regulation of cytokine secretion involved in immune response Source: UniProtKBInferred from direct assayⁱ
  • "The inhibitory receptor LILRB1 modulates the differentiation and regulatory potential of human dendritic cells."
    Young N.T., Waller E.C., Patel R., Roghanian A., Austyn J.M., Trowsdale J.
    Blood 111:3090-3096(2008) [PubMed] [Europe PMC] [Abstract]
• negative regulation of dendritic cell apoptotic process Source: UniProtKBInferred from direct assayⁱ
  • "The inhibitory receptor LILRB1 modulates the differentiation and regulatory potential of human dendritic cells."
    Young N.T., Waller E.C., Patel R., Roghanian A., Austyn J.M., Trowsdale J.
    Blood 111:3090-3096(2008) [PubMed] [Europe PMC] [Abstract]
• negative regulation of dendritic cell differentiation Source: UniProtKB <p>Inferred from Mutant Phenotype</p> <p>Describes annotations that are concluded from looking at variations or changes in a gene product such as mutations or abnormal levels and includes techniques such as knockouts, overexpression, anti-sense experiments and use of specific protein inhibitors.</p> <p>More information in the <a href="http://geneontology.org/page/guide-go-evidence-codes#imp">GO evidence code guide</a></p> Inferred from mutant phenotypeⁱ
  • "HLA class I molecules regulate IFN-gamma production induced in NK cells by target cells, viral products, or immature dendritic cells through the inhibitory receptor ILT2/CD85j."
    Morel E., Bellon T.
    J. Immunol. 181:2368-2381(2008) [PubMed] [Europe PMC] [Abstract]
• negative regulation of endocytosis Source: UniProtKBInferred from direct assayⁱ
  • "The inhibitory receptor LILRB1 modulates the differentiation and regulatory potential of human dendritic cells."
    Young N.T., Waller E.C., Patel R., Roghanian A., Austyn J.M., Trowsdale J.
    Blood 111:3090-3096(2008) [PubMed] [Europe PMC] [Abstract]
• negative regulation of interferon-beta secretion Source: UniProtKBInferred from direct assayⁱ
  • "High affinity soluble ILT2 receptor: a potent inhibitor of CD8(+) T cell activation."
    Moysey R.K., Li Y., Paston S.J., Baston E.E., Sami M.S., Cameron B.J., Gavarret J., Todorov P., Vuidepot A., Dunn S.M., Pumphrey N.J., Adams K.J., Yuan F., Dennis R.E., Sutton D.H., Johnson A.D., Brewer J.E., Ashfield R., Lissin N.M., Jakobsen B.K.
    Protein Cell 1:1118-1127(2010) [PubMed] [Europe PMC] [Abstract]
• negative regulation of interferon-gamma biosynthetic process Source: UniProtKBInferred from direct assayⁱ
  • "HLA class I molecules regulate IFN-gamma production induced in NK cells by target cells, viral products, or immature dendritic cells through the inhibitory receptor ILT2/CD85j."
    Morel E., Bellon T.
    J. Immunol. 181:2368-2381(2008) [PubMed] [Europe PMC] [Abstract]
• negative regulation of interferon-gamma production Source: UniProtKBInferred from direct assayⁱ
  • "Structural elements underlying the high binding affinity of human cytomegalovirus UL18 to leukocyte immunoglobulin-like receptor-1."
    Wagner C.S., Rolle A., Cosman D., Ljunggren H.G., Berndt K.D., Achour A.
    J. Mol. Biol. 373:695-705(2007) [PubMed] [Europe PMC] [Abstract]
• negative regulation of interleukin-10 secretion Source: UniProtKBInferred from direct assayⁱ
  • "The inhibitory receptor LILRB1 modulates the differentiation and regulatory potential of human dendritic cells."
    Young N.T., Waller E.C., Patel R., Roghanian A., Austyn J.M., Trowsdale J.
    Blood 111:3090-3096(2008) [PubMed] [Europe PMC] [Abstract]
• negative regulation of interleukin-12 secretion Source: UniProtKBInferred from direct assayⁱ
  • "The inhibitory receptor LILRB1 modulates the differentiation and regulatory potential of human dendritic cells."
    Young N.T., Waller E.C., Patel R., Roghanian A., Austyn J.M., Trowsdale J.
    Blood 111:3090-3096(2008) [PubMed] [Europe PMC] [Abstract]
• negative regulation of mononuclear cell proliferation Source: UniProtKBInferred from direct assayⁱ
  • "Analysis of expression and function of the inhibitory receptor ILT2 in lymphocytes from patients with autoimmune thyroid disease."
    Doniz-Padilla L., Paniagua A.E., Sandoval-Correa P., Monsivais-Urenda A., Leskela S., Marazuela M., Gonzalez-Amaro R.
    Eur. J. Endocrinol. 165:129-136(2011) [PubMed] [Europe PMC] [Abstract]
• negative regulation of natural killer cell mediated cytotoxicity Source: UniProtKBInferred from direct assayⁱ
  • "Complexes of HLA-G protein on the cell surface are important for leukocyte Ig-like receptor-1 function."
    Gonen-Gross T., Achdout H., Gazit R., Hanna J., Mizrahi S., Markel G., Goldman-Wohl D., Yagel S., Horejsi V., Levy O., Baniyash M., Mandelboim O.
    J. Immunol. 171:1343-1351(2003) [PubMed] [Europe PMC] [Abstract]
  • "The CD85j+ NK cell subset potently controls HIV-1 replication in autologous dendritic cells."
    Scott-Algara D., Arnold V., Didier C., Kattan T., Pirozzi G., Barre-Sinoussi F., Pancino G.
    PLoS ONE 3:e1975-e1975(2008) [PubMed] [Europe PMC] [Abstract]
• negative regulation of osteoclast development Source: UniProtKBInferred from direct assayⁱ
  • "Inhibitory immunoglobulin-like receptors LILRB and PIR-B negatively regulate osteoclast development."
    Mori Y., Tsuji S., Inui M., Sakamoto Y., Endo S., Ito Y., Fujimura S., Koga T., Nakamura A., Takayanagi H., Itoi E., Takai T.
    J. Immunol. 181:4742-4751(2008) [PubMed] [Europe PMC] [Abstract]
• negative regulation of serotonin secretion Source: UniProtKBInferred from direct assayⁱ
  • Ref.11

    "Mutational analysis of immunoreceptor tyrosine-based inhibition motifs of the Ig-like transcript 2 (CD85j) leukocyte receptor."
    Bellon T., Kitzig F., Sayos J., Lopez-Botet M.
    J. Immunol. 168:3351-3359(2002) [PubMed] [Europe PMC] [Abstract]

    Cited for: PHOSPHORYLATION AT TYR-533; TYR-614 AND TYR-644, MUTAGENESIS OF TYR-533; TYR-562; TYR-614 AND TYR-644, INTERACTION WITH FCER1A, FUNCTION.
• negative regulation of T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell Source: UniProtKBInferred from direct assayⁱ
  • "The inhibitory receptor LILRB1 modulates the differentiation and regulatory potential of human dendritic cells."
    Young N.T., Waller E.C., Patel R., Roghanian A., Austyn J.M., Trowsdale J.
    Blood 111:3090-3096(2008) [PubMed] [Europe PMC] [Abstract]
• negative regulation of T cell mediated cytotoxicity Source: UniProtKBInferred from direct assayⁱ
  • "High affinity soluble ILT2 receptor: a potent inhibitor of CD8(+) T cell activation."
    Moysey R.K., Li Y., Paston S.J., Baston E.E., Sami M.S., Cameron B.J., Gavarret J., Todorov P., Vuidepot A., Dunn S.M., Pumphrey N.J., Adams K.J., Yuan F., Dennis R.E., Sutton D.H., Johnson A.D., Brewer J.E., Ashfield R., Lissin N.M., Jakobsen B.K.
    Protein Cell 1:1118-1127(2010) [PubMed] [Europe PMC] [Abstract]
• negative regulation of T cell proliferation Source: UniProtKBInferred from direct assayⁱ
  • "Coordinated expression of Ig-like inhibitory MHC class I receptors and acquisition of cytotoxic function in human CD8+ T cells."
    Anfossi N., Doisne J.M., Peyrat M.A., Ugolini S., Bonnaud O., Bossy D., Pitard V., Merville P., Moreau J.F., Delfraissy J.F., Dechanet-Merville J., Bonneville M., Venet A., Vivier E.
    J. Immunol. 173:7223-7229(2004) [PubMed] [Europe PMC] [Abstract]
• negative regulation of transforming growth factor-beta secretion Source: UniProtKBInferred from direct assayⁱ
  • "The inhibitory receptor LILRB1 modulates the differentiation and regulatory potential of human dendritic cells."
    Young N.T., Waller E.C., Patel R., Roghanian A., Austyn J.M., Trowsdale J.
    Blood 111:3090-3096(2008) [PubMed] [Europe PMC] [Abstract]
• negative regulation of tumor necrosis factor biosynthetic process Source: UniProtKBInferred from direct assayⁱ
  • "HLA class I molecules regulate IFN-gamma production induced in NK cells by target cells, viral products, or immature dendritic cells through the inhibitory receptor ILT2/CD85j."
    Morel E., Bellon T.
    J. Immunol. 181:2368-2381(2008) [PubMed] [Europe PMC] [Abstract]
• positive regulation of apoptotic process Source: UniProtKBInferred from direct assayⁱ
  • "Analysis of expression and function of the inhibitory receptor ILT2 in lymphocytes from patients with autoimmune thyroid disease."
    Doniz-Padilla L., Paniagua A.E., Sandoval-Correa P., Monsivais-Urenda A., Leskela S., Marazuela M., Gonzalez-Amaro R.
    Eur. J. Endocrinol. 165:129-136(2011) [PubMed] [Europe PMC] [Abstract]
• positive regulation of cytolysis Source: UniProtKBInferred from direct assayⁱ
  • "HLA class I molecules regulate IFN-gamma production induced in NK cells by target cells, viral products, or immature dendritic cells through the inhibitory receptor ILT2/CD85j."
    Morel E., Bellon T.
    J. Immunol. 181:2368-2381(2008) [PubMed] [Europe PMC] [Abstract]
• positive regulation of defense response to virus by host Source: UniProtKBInferred from direct assayⁱ
  • "The CD85j+ NK cell subset potently controls HIV-1 replication in autologous dendritic cells."
    Scott-Algara D., Arnold V., Didier C., Kattan T., Pirozzi G., Barre-Sinoussi F., Pancino G.
    PLoS ONE 3:e1975-e1975(2008) [PubMed] [Europe PMC] [Abstract]
• positive regulation of gamma-delta T cell activation involved in immune response Source: UniProtKBInferred from direct assayⁱ
  • "Up-regulation of cytolytic functions of human Vdelta2-gamma T lymphocytes through engagement of ILT2 expressed by tumor target cells."
    Harly C., Peyrat M.A., Netzer S., Dechanet-Merville J., Bonneville M., Scotet E.
    Blood 117:2864-2873(2011) [PubMed] [Europe PMC] [Abstract]
• positive regulation of gene expression Source: UniProtKBInferred from direct assayⁱ
  • "The inhibitory receptor LILRB1 modulates the differentiation and regulatory potential of human dendritic cells."
    Young N.T., Waller E.C., Patel R., Roghanian A., Austyn J.M., Trowsdale J.
    Blood 111:3090-3096(2008) [PubMed] [Europe PMC] [Abstract]
• positive regulation of macrophage cytokine production Source: UniProtKBInferred from direct assayⁱ
  • Ref.13

    "HLA-G homodimer-induced cytokine secretion through HLA-G receptors on human decidual macrophages and natural killer cells."
    Li C., Houser B.L., Nicotra M.L., Strominger J.L.
    Proc. Natl. Acad. Sci. U.S.A. 106:5767-5772(2009) [PubMed] [Europe PMC] [Abstract]

    Cited for: TISSUE SPECIFICITY, FUNCTION.
• positive regulation of transcription by RNA polymerase II Source: BHF-UCLNon-traceable author statementⁱ
  • "Modulation of dendritic cell differentiation by HLA-G and ILT4 requires the IL-6--STAT3 signaling pathway."
    Liang S., Ristich V., Arase H., Dausset J., Carosella E.D., Horuzsko A.
    Proc. Natl. Acad. Sci. U.S.A. 105:8357-8362(2008) [PubMed] [Europe PMC] [Abstract]
• receptor internalization Source: UniProtKB <p>Traceable Author Statement</p> <p>Used for information from review articles where the original experiments are traceable through that article and also for information from text books or dictionaries.</p> <p>More information in the <a href="http://geneontology.org/page/guide-go-evidence-codes#tas">GO evidence code guide</a></p> Traceable author statementⁱ
  • "Structural elements underlying the high binding affinity of human cytomegalovirus UL18 to leukocyte immunoglobulin-like receptor-1."
    Wagner C.S., Rolle A., Cosman D., Ljunggren H.G., Berndt K.D., Achour A.
    J. Mol. Biol. 373:695-705(2007) [PubMed] [Europe PMC] [Abstract]
• regulation of immune response Source: Reactome
• response to virus Source: UniProtKBInferred from direct assayⁱ
  • "Structural elements underlying the high binding affinity of human cytomegalovirus UL18 to leukocyte immunoglobulin-like receptor-1."
    Wagner C.S., Rolle A., Cosman D., Ljunggren H.G., Berndt K.D., Achour A.
    J. Mol. Biol. 373:695-705(2007) [PubMed] [Europe PMC] [Abstract]
  • "The inhibitory receptor LILRB1 modulates the differentiation and regulatory potential of human dendritic cells."
    Young N.T., Waller E.C., Patel R., Roghanian A., Austyn J.M., Trowsdale J.
    Blood 111:3090-3096(2008) [PubMed] [Europe PMC] [Abstract]
  • Ref.2

    "A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules."
    Cosman D., Fanger N., Borges L., Kubin M., Chin W., Peterson L., Hsu M.-L.
    Immunity 7:273-282(1997) [PubMed] [Europe PMC] [Abstract]

    Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 3), VARIANTS PRO-68; THR-142; ILE-155 AND LYS-625, INTERACTION WITH H301 AND PTPN6, PHOSPHORYLATION, TISSUE SPECIFICITY, FUNCTION.
• signal transduction Source: UniProtKBInferred from direct assayⁱ
  • "Inhibitory immunoglobulin-like receptors LILRB and PIR-B negatively regulate osteoclast development."
    Mori Y., Tsuji S., Inui M., Sakamoto Y., Endo S., Ito Y., Fujimura S., Koga T., Nakamura A., Takayanagi H., Itoi E., Takai T.
    J. Immunol. 181:4742-4751(2008) [PubMed] [Europe PMC] [Abstract]
• T cell proliferation involved in immune response Source: UniProtKBInferred from direct assayⁱ
  • "The inhibitory receptor LILRB1 modulates the differentiation and regulatory potential of human dendritic cells."
    Young N.T., Waller E.C., Patel R., Roghanian A., Austyn J.M., Trowsdale J.
    Blood 111:3090-3096(2008) [PubMed] [Europe PMC] [Abstract]

<p>UniProtKB Keywords constitute a <a href="http://www.uniprot.org/keywords">controlled vocabulary</a> with a hierarchical structure. Keywords summarise the content of a UniProtKB entry and facilitate the search for proteins of interest.<p><a href='/help/keywords' target='_top'>More...</a></p>Keywordsⁱ

Enzyme and pathway databases

<p>This section provides information about the protein and gene name(s) and synonym(s) and about the organism that is the source of the protein sequence.<p><a href='/help/names_and_taxonomy_section' target='_top'>More...</a></p>Names & Taxonomyⁱ

Organism-specific databases

<p>This section provides information on the location and the topology of the mature protein in the cell.<p><a href='/help/subcellular_location_section' target='_top'>More...</a></p>Subcellular locationⁱ

Topology

Keywords - Cellular componentⁱ

<p>This section provides information on the disease(s) and phenotype(s) associated with a protein.<p><a href='/help/pathology_and_biotech_section' target='_top'>More...</a></p>Pathology & Biotechⁱ

Mutagenesis

Organism-specific databases

Miscellaneous databases

Polymorphism and mutation databases

<p>This section describes post-translational modifications (PTMs) and/or processing events.<p><a href='/help/ptm_processing_section' target='_top'>More...</a></p>PTM / Processingⁱ

Molecule processing

Amino acid modifications

<p>This subsection of the <a href="http://www.uniprot.org/help/ptm_processing_section">PTM/processing</a> section describes post-translational modifications (PTMs). This subsection <strong>complements</strong> the information provided at the sequence level or describes modifications for which <strong>position-specific data is not yet available</strong>.<p><a href='/help/post-translational_modification' target='_top'>More...</a></p>Post-translational modificationⁱ

Keywords - PTMⁱ

Proteomic databases

PTM databases

<p>This section provides information on the expression of a gene at the mRNA or protein level in cells or in tissues of multicellular organisms.<p><a href='/help/expression_section' target='_top'>More...</a></p>Expressionⁱ

<p>This subsection of the ‘Expression’ section provides information on the expression of a gene at the mRNA or protein level in cells or in tissues of multicellular organisms. By default, the information is derived from experiments at the mRNA level, unless specified ‘at protein level’. <br></br>Examples: <a href="http://www.uniprot.org/uniprot/P92958#expression">P92958</a>, <a href="http://www.uniprot.org/uniprot/Q8TDN4#expression">Q8TDN4</a>, <a href="http://www.uniprot.org/uniprot/O14734#expression">O14734</a><p><a href='/help/tissue_specificity' target='_top'>More...</a></p>Tissue specificityⁱ

<p>This section provides information on the quaternary structure of a protein and on interaction(s) with other proteins or protein complexes.<p><a href='/help/interaction_section' target='_top'>More...</a></p>Interactionⁱ

<p>This subsection of the <a href="http://www.uniprot.org/help/interaction_section">'Interaction'</a> section provides information about the protein quaternary structure and interaction(s) with other proteins or protein complexes (with the exception of physiological receptor-ligand interactions which are annotated in the <a href="http://www.uniprot.org/help/function_section">'Function'</a> section).<p><a href='/help/subunit_structure' target='_top'>More...</a></p>Subunit structureⁱ

<p>This subsection of the '<a href="http://www.uniprot.org/help/interaction_section%27">Interaction</a> section provides information about binary protein-protein interactions. The data presented in this section are a quality-filtered subset of binary interactions automatically derived from the <a href="http://www.ebi.ac.uk/intact/">IntAct database</a>. It is updated on a monthly basis. Each binary interaction is displayed on a separate line.<p><a href='/help/binary_interactions' target='_top'>More...</a></p>Binary interactionsⁱ

GO - Molecular functionⁱ

• MHC class Ib protein binding Source: UniProtKBInferred from direct assayⁱ
  • "Functional characterization of HLA-F and binding of HLA-F tetramers to ILT2 and ILT4 receptors."
    Lepin E.J., Bastin J.M., Allan D.S., Roncador G., Braud V.M., Mason D.Y., van der Merwe P.A., McMichael A.J., Bell J.I., Powis S.H., O'Callaghan C.A.
    Eur. J. Immunol. 30:3552-3561(2000) [PubMed] [Europe PMC] [Abstract]
• MHC class I protein binding Source: UniProtKBInferred from direct assayⁱ
  • "The inhibitory receptor LILRB1 modulates the differentiation and regulatory potential of human dendritic cells."
    Young N.T., Waller E.C., Patel R., Roghanian A., Austyn J.M., Trowsdale J.
    Blood 111:3090-3096(2008) [PubMed] [Europe PMC] [Abstract]
  • "Inhibitory immunoglobulin-like receptors LILRB and PIR-B negatively regulate osteoclast development."
    Mori Y., Tsuji S., Inui M., Sakamoto Y., Endo S., Ito Y., Fujimura S., Koga T., Nakamura A., Takayanagi H., Itoi E., Takai T.
    J. Immunol. 181:4742-4751(2008) [PubMed] [Europe PMC] [Abstract]
  • "High affinity soluble ILT2 receptor: a potent inhibitor of CD8(+) T cell activation."
    Moysey R.K., Li Y., Paston S.J., Baston E.E., Sami M.S., Cameron B.J., Gavarret J., Todorov P., Vuidepot A., Dunn S.M., Pumphrey N.J., Adams K.J., Yuan F., Dennis R.E., Sutton D.H., Johnson A.D., Brewer J.E., Ashfield R., Lissin N.M., Jakobsen B.K.
    Protein Cell 1:1118-1127(2010) [PubMed] [Europe PMC] [Abstract]
  • Ref.9

    "The MHC class I binding proteins LIR-1 and LIR-2 inhibit Fc receptor-mediated signaling in monocytes."
    Fanger N.A., Cosman D., Peterson L., Braddy S.C., Maliszewski C.R., Borges L.
    Eur. J. Immunol. 28:3423-3434(1998) [PubMed] [Europe PMC] [Abstract]

    Cited for: INTERACTION WITH PTPN6 AND FCGR1A, PHOSPHORYLATION, TISSUE SPECIFICITY, FUNCTION.
• protein homodimerization activity Source: UniProtKBInferred from physical interactionⁱ
  • "High affinity soluble ILT2 receptor: a potent inhibitor of CD8(+) T cell activation."
    Moysey R.K., Li Y., Paston S.J., Baston E.E., Sami M.S., Cameron B.J., Gavarret J., Todorov P., Vuidepot A., Dunn S.M., Pumphrey N.J., Adams K.J., Yuan F., Dennis R.E., Sutton D.H., Johnson A.D., Brewer J.E., Ashfield R., Lissin N.M., Jakobsen B.K.
    Protein Cell 1:1118-1127(2010) [PubMed] [Europe PMC] [Abstract]
• protein phosphatase 1 binding Source: UniProtKBInferred from physical interactionⁱ
  • Ref.11

    "Mutational analysis of immunoreceptor tyrosine-based inhibition motifs of the Ig-like transcript 2 (CD85j) leukocyte receptor."
    Bellon T., Kitzig F., Sayos J., Lopez-Botet M.
    J. Immunol. 168:3351-3359(2002) [PubMed] [Europe PMC] [Abstract]

    Cited for: PHOSPHORYLATION AT TYR-533; TYR-614 AND TYR-644, MUTAGENESIS OF TYR-533; TYR-562; TYR-614 AND TYR-644, INTERACTION WITH FCER1A, FUNCTION.
  • "Inhibitory immunoglobulin-like receptors LILRB and PIR-B negatively regulate osteoclast development."
    Mori Y., Tsuji S., Inui M., Sakamoto Y., Endo S., Ito Y., Fujimura S., Koga T., Nakamura A., Takayanagi H., Itoi E., Takai T.
    J. Immunol. 181:4742-4751(2008) [PubMed] [Europe PMC] [Abstract]
  • Ref.2

    "A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules."
    Cosman D., Fanger N., Borges L., Kubin M., Chin W., Peterson L., Hsu M.-L.
    Immunity 7:273-282(1997) [PubMed] [Europe PMC] [Abstract]

    Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 3), VARIANTS PRO-68; THR-142; ILE-155 AND LYS-625, INTERACTION WITH H301 AND PTPN6, PHOSPHORYLATION, TISSUE SPECIFICITY, FUNCTION.
  • Ref.9

    "The MHC class I binding proteins LIR-1 and LIR-2 inhibit Fc receptor-mediated signaling in monocytes."
    Fanger N.A., Cosman D., Peterson L., Braddy S.C., Maliszewski C.R., Borges L.
    Eur. J. Immunol. 28:3423-3434(1998) [PubMed] [Europe PMC] [Abstract]

    Cited for: INTERACTION WITH PTPN6 AND FCGR1A, PHOSPHORYLATION, TISSUE SPECIFICITY, FUNCTION.
• SH2 domain binding Source: UniProtKBInferred from direct assayⁱ
  • Ref.11

    "Mutational analysis of immunoreceptor tyrosine-based inhibition motifs of the Ig-like transcript 2 (CD85j) leukocyte receptor."
    Bellon T., Kitzig F., Sayos J., Lopez-Botet M.
    J. Immunol. 168:3351-3359(2002) [PubMed] [Europe PMC] [Abstract]

    Cited for: PHOSPHORYLATION AT TYR-533; TYR-614 AND TYR-644, MUTAGENESIS OF TYR-533; TYR-562; TYR-614 AND TYR-644, INTERACTION WITH FCER1A, FUNCTION.

Protein-protein interaction databases

<p>This section provides information on the tertiary and secondary structure of a protein.<p><a href='/help/structure_section' target='_top'>More...</a></p>Structureⁱ

Secondary structure

3D structure databases

Miscellaneous databases

<p>This section provides information on sequence similarities with other proteins and the domain(s) present in a protein.<p><a href='/help/family_and_domains_section' target='_top'>More...</a></p>Family & Domainsⁱ

Domains and Repeats

Motif

<p>This subsection of the ‘Family and domains’ section provides general information on the biological role of a domain. The term ‘domain’ is intended here in its wide acceptation, it may be a structural domain, a transmembrane region or a functional domain. Several domains are described in this subsection.<p><a href='/help/domain_cc' target='_top'>More...</a></p>Domainⁱ

Keywords - Domainⁱ

Phylogenomic databases

Family and domain databases

<p>This section displays by default the canonical protein sequence and upon request all isoforms described in the entry. It also includes information pertinent to the sequence(s), including <a href="http://www.uniprot.org/help/sequence_length">length</a> and <a href="http://www.uniprot.org/help/sequences">molecular weight</a>. The information is filed in different subsections. The current subsections and their content are listed below:<p><a href='/help/sequences_section' target='_top'>More...</a></p>Sequences (5+)ⁱ

<p>This subsection of the <a href="http://www.uniprot.org/help/sequences_section">Sequence</a> section indicates if the <a href="http://www.uniprot.org/help/canonical_and_isoforms">canonical sequence</a> displayed by default in the entry is complete or not.<p><a href='/help/sequence_status' target='_top'>More...</a></p>Sequence statusⁱ: Complete.

<p>This subsection of the <a href="http://www.uniprot.org/help/sequences_section">Sequence</a> section indicates if the <a href="http://www.uniprot.org/help/canonical_and_isoforms">canonical sequence</a> displayed by default in the entry is in its mature form or if it represents the precursor.<p><a href='/help/sequence_processing' target='_top'>More...</a></p>Sequence processingⁱ: The displayed sequence is further processed into a mature form.

This entry has 5 described isoforms and 19 potential isoforms that are computationally mapped.Show allAlign All

        10         20         30         40         50
MTPILTVLIC LGLSLGPRTH VQAGHLPKPT LWAEPGSVIT QGSPVTLRCQ 
        60         70         80         90        100
GGQETQEYRL YREKKTALWI TRIPQELVKK GQFPIPSITW EHAGRYRCYY 
       110        120        130        140        150
GSDTAGRSES SDPLELVVTG AYIKPTLSAQ PSPVVNSGGN VILQCDSQVA 
       160        170        180        190        200
FDGFSLCKEG EDEHPQCLNS QPHARGSSRA IFSVGPVSPS RRWWYRCYAY 
       210        220        230        240        250
DSNSPYEWSL PSDLLELLVL GVSKKPSLSV QPGPIVAPEE TLTLQCGSDA 
       260        270        280        290        300
GYNRFVLYKD GERDFLQLAG AQPQAGLSQA NFTLGPVSRS YGGQYRCYGA 
       310        320        330        340        350
HNLSSEWSAP SDPLDILIAG QFYDRVSLSV QPGPTVASGE NVTLLCQSQG 
       360        370        380        390        400
WMQTFLLTKE GAADDPWRLR STYQSQKYQA EFPMGPVTSA HAGTYRCYGS 
       410        420        430        440        450
QSSKPYLLTH PSDPLELVVS GPSGGPSSPT TGPTSTSGPE DQPLTPTGSD 
       460        470        480        490        500
PQSGLGRHLG VVIGILVAVI LLLLLLLLLF LILRHRRQGK HWTSTQRKAD 
       510        520        530        540        550
FQHPAGAVGP EPTDRGLQWR SSPAADAQEE NLYAAVKHTQ PEDGVEMDTR 
       560        570        580        590        600
SPHDEDPQAV TYAEVKHSRP RREMASPPSP LSGEFLDTKD RQAEEDRQMD 
       610        620        630        640        650
TEAAASEAPQ DVTYAQLHSL TLRREATEPP PSQEGPSPAV PSIYATLAIH 

        10         20         30         40         50
MTPILTVLIC LGLSLGPRTH VQAGHLPKPT LWAEPGSVIT QGSPVTLRCQ 
        60         70         80         90        100
GGQETQEYRL YREKKTALWI TRIPQELVKK GQFPIPSITW EHAGRYRCYY 
       110        120        130        140        150
GSDTAGRSES SDPLELVVTG AYIKPTLSAQ PSPVVNSGGN VILQCDSQVA 
       160        170        180        190        200
FDGFSLCKEG EDEHPQCLNS QPHARGSSRA IFSVGPVSPS RRWWYRCYAY 
       210        220        230        240        250
DSNSPYEWSL PSDLLELLVL GVSKKPSLSV QPGPIVAPEE TLTLQCGSDA 
       260        270        280        290        300
GYNRFVLYKD GERDFLQLAG AQPQAGLSQA NFTLGPVSRS YGGQYRCYGA 
       310        320        330        340        350
HNLSSEWSAP SDPLDILIAG QFYDRVSLSV QPGPTVASGE NVTLLCQSQG 
       360        370        380        390        400
WMQTFLLTKE GAADDPWRLR STYQSQKYQA EFPMGPVTSA HAGTYRCYGS 
       410        420        430        440        450
QSSKPYLLTH PSDPLELVVS GPSGGPSSPT TGPTSTSAGP EDQPLTPTGS 
       460        470        480        490        500
DPQSGLGRHL GVVIGILVAV ILLLLLLLLL FLILRHRRQG KHWTSTQRKA 
       510        520        530        540        550
DFQHPAGAVG PEPTDRGLQW RSSPAADAQE ENLYAAVKHT QPEDGVEMDT 
       560        570        580        590        600
RSPHDEDPQA VTYAEVKHSR PRREMASPPS PLSGEFLDTK DRQAEEDRQM 
       610        620        630        640        650
DTEAAASEAP QDVTYAQLHS LTLRREATEP PPSQEGPSPA VPSIYATLAI 

H                                                      

        10         20         30         40         50
MTPILTVLIC LGLSLGPRTH VQAGHLPKPT LWAEPGSVIT QGSPVTLRCQ 
        60         70         80         90        100
GGQETQEYRL YREKKTALWI TRIPQELVKK GQFPIPSITW EHAGRYRCYY 
       110        120        130        140        150
GSDTAGRSES SDPLELVVTG AYIKPTLSAQ PSPVVNSGGN VILQCDSQVA 
       160        170        180        190        200
FDGFSLCKEG EDEHPQCLNS QPHARGSSRA IFSVGPVSPS RRWWYRCYAY 
       210        220        230        240        250
DSNSPYEWSL PSDLLELLVL GVSKKPSLSV QPGPIVAPEE TLTLQCGSDA 
       260        270        280        290        300
GYNRFVLYKD GERDFLQLAG AQPQAGLSQA NFTLGPVSRS YGGQYRCYGA 
       310        320        330        340        350
HNLSSEWSAP SDPLDILIAG QFYDRVSLSV QPGPTVASGE NVTLLCQSQG 
       360        370        380        390        400
WMQTFLLTKE GAADDPWRLR STYQSQKYQA EFPMGPVTSA HAGTYRCYGS 
       410        420        430        440        450
QSSKPYLLTH PSDPLELVVS GPSGGPSSPT TGPTSTSAGP EDQPLTPTGS 
       460        470        480        490        500
DPQSGLGRHL GVVIGILVAV ILLLLLLLLL FLILRHRRQG KHWTSTQRKA 
       510        520        530        540        550
DFQHPAGAVG PEPTDRGLQW RSSPAADAQE ENLYAAVKHT QPEDGVEMDT 
       560        570        580        590        600
RQSPHDEDPQ AVTYAEVKHS RPRREMASPP SPLSGEFLDT KDRQAEEDRQ 
       610        620        630        640        650
MDTEAAASEA PQDVTYAQLH SLTLRREATE PPPSQEGPSP AVPSIYATLA 

IH                                                     

        10         20         30         40         50
MTPILTVLIC LGLSLGPRTH VQAGHLPKPT LWAEPGSVIT QGSPVTLRCQ 
        60         70         80         90        100
GGQETQEYRL YREKKTALWI TRIPQELVKK GQFPIPSITW EHAGRYRCYY 
       110        120        130        140        150
GSDTAGRSES SDPLELVVTG AYIKPTLSAQ PSPVVNSGGN VILQCDSQVA 
       160        170        180        190        200
FDGFSLCKEG EDEHPQCLNS QPHARGSSRA IFSVGPVSPS RRWWYRCYAY 
       210        220        230        240        250
DSNSPYEWSL PSDLLELLVL GVSKKPSLSV QPGPIVAPEE TLTLQCGSDA 
       260        270        280        290        300
GYNRFVLYKD GERDFLQLAG AQPQAGLSQA NFTLGPVSRS YGGQYRCYGA 
       310        320        330        340        350
HNLSSEWSAP SDPLDILIAG QFYDRVSLSV QPGPTVASGE NVTLLCQSQG 
       360        370        380        390        400
WMQTFLLTKE GAADDPWRLR STYQSQKYQA EFPMGPVTSA HAGTYRCYGS 
       410        420        430        440        450
QSSKPYLLTH PSDPLELVVS GPSGGPSSPT TGPTSTSGPE DQPLTPTGSD 
       460        470        480        490        500
PQSGLGRHLG VVIGILVAVI LLLLLLLLLF LILRHRRQGK HWTSTQRKAD 
       510        520        530        540        550
FQHPAGAVGP EPTDRGLQWR SSPAADAQEE NLYAAVKHTQ PEDGVEMDTR 
       560        570        580        590        600
QSPHDEDPQA VTYAEVKHSR PRREMASPPS PLSGEFLDTK DRQAEEDRQM 
       610        620        630        640        650
DTEAAASEAP QDVTYAQLHS LTLRREATEP PPSQEGPSPA VPSIYATLAI 

H                                                      

        10         20         30         40         50
MTPILTVLIC LGLSLGPRTH VQAGHLPKPT LWAEPGSVIT QGSPVTLRCQ 
        60         70         80         90        100
GGQETQEYRL YREKKTALWI TRIPQELVKK GQFPIPSITW EHAGRYRCYY 
       110        120        130        140        150
GSDTAGRSES SDPLELVVTG AYIKPTLSAQ PSPVVNSGGN VILQCDSQVA 
       160        170        180        190        200
FDGFSLCKEG EDEHPQCLNS QPHARGSSRA IFSVGPVSPS RRWWYRCYAY 
       210        220        230        240        250
DSNSPYEWSL PSDLLELLVL GVSKKPSLSV QPGPIVAPEE TLTLQCGSDA 
       260        270        280        290        300
GYNRFVLYKD GERDFLQLAG AQPQAGLSQA NFTLGPVSRS YGGQYRCYGA 
       310        320        330        340        350
HNLSSEWSAP SDPLDILIAG QFYDRVSLSV QPGPTVASGE NVTLLCQSQG 
       360        370        380        390        400
WMQTFLLTKE GAADDPWRLR STYQSQKYQA EFPMGPVTSA HAGTYRCYGS 
       410        420        430        440        450
QSSKPYLLTH PSDPLELVVS GPSGGPSSPT TGPTSTSAGP EDQPLTPTGS 

DPQSGE                                                 

Experimental Info

Natural variant

Alternative sequence

Sequence databases

Genome annotation databases

Keywords - Coding sequence diversityⁱ